Abstract
To investigate the association between beta1-adrenergic receptor (ADRB1) polymorphisms and response to bisoprolol treatment in beta-blocker naive patients with acute coronary syndrome (ACS). Seventy-seven patients received bisoprolol for four weeks. Blood pressure and heart rate were measured at baseline and during treatment. TaqMan allelic discrimination method was utilized for ADRB1 Ser49Gly and Arg389Gly genotyping. Arg389Arg carriers showed greater reductions in systolic and diastolic blood pressure (-8.5%±7.8% vs -0.76%±8.7%, p=0.000218), and (-9.5%±9.7% vs -0.80%±11.5%, p=0.000149), respectively, compared with Gly389 carriers. No statistical difference was found for study's outcomes based on codon 49. Arg389Gly polymorphism is a promising bisoprolol response predictor in ACS patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
